Sulphinpyrazone inhibits development of atherosclerosis in rabbits.
The influence of sulphinpyrazone (SP) on the development of atherosclerosis in rabbits was examined. SP administered orally at a dose of 100 mg daily inhibited the formation of atherosclerotic plaques in arteries. At the same time SP suppressed platelet aggregability to collagen.
D000818:Animals; D001161:Arteriosclerosis / Q000517:prevention & control*; D004036:Diet, Atherogenic; D008297:Male; D010974:Platelet Aggregation / Q000187:drug effects; D011817:Rabbits; D013442:Sulfinpyrazone / Q000627:therapeutic use*
D013442:Sulfinpyrazone